BioNexus Gene Lab Stock

BioNexus Gene Lab EBIT per Share

The EBIT per Share of BioNexus Gene Lab (BGLC) as of Sep 9, 2026 is -0.94 USD. In the previous year, EBIT per Share was -1.63 USD — a change of -42.23% (higher).

EBIT per Share

-0.94USD

YoY

-42.23%

Last updated:

EBIT per Share of BioNexus Gene Lab is 2026 -0.94 USD. EBIT per Share of BioNexus Gene Lab was 2025 -1.63 USD. It decreases by -42.23% higher compared to the previous year.

The BioNexus Gene Lab EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
-0.22 USD
Jan 1, 2018
0.11 USD
Jan 1, 2019
-0.39 USD
Jan 1, 2020
1.48 USD
Jan 1, 2021
0.74 USD
Jan 1, 2022
-0.20 USD
Jan 1, 2023
-1.63 USD
Jan 1, 2024
-0.94 USD
The BioNexus Gene Lab EBIT per Share history
YEAREBIT per ShareYoY
-0.94USD-42.23%
-1.63USD+711.76%
-0.20USD-127.35%
0.74USD-50.30%
1.48USD-480.59%
-0.39USD-458.45%
0.11USD-150.00%
-0.22USD—
Access this data via the Eulerpool API
Get Free API Key

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

EBIT per Share of BioNexus Gene Lab is -0.94 USD in 2026.

EBIT per Share of BioNexus Gene Lab changed from -1.63 USD to -0.94 USD, representing a -42.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — BioNexus Gene Lab

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — BioNexus Gene Lab